minimal residual disease

IRVINE, California, May 29, 2026 PeproMene Bio, Inc. has announced that updated clinical data from its ongoing Phase 1...

LUND, Sweden, May 27, 2026 Hansa Biopharma AB has announced positive topline results from its European Post Authorization Efficacy...

BOSTON, May 27, 2026 TransCode Therapeutics, Inc., a clinical-stage biotechnology company focused on RNA-based cancer therapeutics, has announced the...

Toronto, Ontario, December 18, 2025 — Telo Genomics Corp. has initiated a new retrospective blood-based minimal residual disease (MRD)...